Search
ACRUX LIMITED (ACR)

ACRUX LIMITED (ACR)

  Print

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Acrux Limited
Stock Code: ACR
Website: www.acrux.com.au
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 589
Equiv. Shares (M): 166

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 3.460 $ 3.550 $ 3.580 $ 3.460 $ 3.540 412,648 $ -0.080  -2.260 %

Current Broker Consensus Recommendation more
Recommendation: Buy
Recommendation Date: 2nd Feb 2012
12 Month Target Price (average): $4.31
Brokers Surveyed: 1

Company Overview

Business Description:
Acrux Limited (ACR) is an Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin.

Strategy Analysis:
ACR intends to progress candidate products a significant way down the development path, ideally until the end of Phase 3 clinical trials, as the potential value capture more than justifying the risk of failure. A product already in market validates the core delivery technology, thereby significantly reducing future development risk. ACR will engage marketing partners to commercialize product. ACR may license out the technology for the development of applications in instances where it considers it has inadequate expertise or resources. Acrux reported NPAT up 23% to $57.49m for the year ended 30 June 2011. Revenues from ordinary activities were $93.47m, up 67% from the same period last year. Diluted EPS was 34.51 cents compared to 28.70 cents last year. Net operating cash flow was $65.10m compared to $48.37m last year. The final dividend declared was 60 cents, taking the full year dividend to 60 cents compared with nil cents last year.


Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2013  F 21.0 12.6 NaN 28.1 0.0 0.0 100.0
2012  F 1.4 0.8 -97.6 421.4 0.0 0.0 0.0
2011  A 57.0 34.4 19.9 8.6 60.0 20.2 0.0
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2011 A 2012 F 2013 F 2011 A 2012 F 2013 F 2011 A 2012 F 2013 F
Acrux Limited (ACR) $601 M 0.2024 -0.9757 14.0238 10.4607 429.7619 28.6054 0.0000 0.0000 0.0000
Pharmaxis (PXS) $307 M -- -- -- -- -- -- 0.0000 -- --

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
ACR 3.00 25.1 12.9 10.00 6.54
Market 0.82 12.5 1.38 1.21 1.90
Sector 0.75 16.9 2.28 1.55 5.95

Directors
Name Position Start Date
Dr Richard Treagus Chief Executive Officer, Managing Director 03 April 2007
Mr Ross Dobinson Non-Executive Chairman 19 March 1999
Mr Henry Kenneth Windle Non-Executive Deputy Chairman 28 February 2001

Management
Name Position
Jon Pilcher Chief Finance Officer,Company Secretary
A Watkinson Chief Scientific Officer
Hugh Alsop Director of Business Development
N Webster Director of Business Development
T Soulis Director of Clinical Development
Clive Blower Director of Product Development and Technical Affairs

Substantial Shareholders
Holding Name
20,499,214 (12.31%) Orbis Global Equity Fund Limited

Calendar of Events
Date Event
19 October 2012 Report (Annual)
21 August 2012 Report (Prelim)
23 February 2012 Report (Interim)
Search for Managed Funds, Superannuation Funds and Retirement Funds Find a Managed Fund Reduce your fees and save money on your Managed Funds with our 100% Entry Fee Rebate 100% Entry Fee Rebate

Login
Email
Password
     Log me in automatically in future
Forgotten password? | Secure Login | Terms & Conditions
Free Membership

Membership benefits...

  • 100% entry fee rebates
  • Cash back on your managed fund investments with our innovative TrailCap™ program
  • Independent research on...
    • over 1,000 managed funds
    • over 300 ASX-listed Companies
    • top performing suburbs/postcodes
  • Access to IPOs/floats & other investment offers
  • Superior investment tools...
    • Portfolio manager
    • Watchlists
    • Alerts
  • Regular investment e-newsletter

Advertisement

Portfolio / Watchlist

Start a new portfolio / view your existing portfolio.
Track all your assets and manage your investments easily.

Trade Shares Online from $19.95^

eNewsletter

Keep up to date with new investments and important news - subscribe to our FREE weekly eNewsletters. Sign up now!

Free Guides

The Essential Guide to Leveraged Trading using CFDs

An educational booklet that outlines the different types of Contracts for Difference (CFDs) available in Australia.

More details...


News

Obama hoses down talk of Israeli strikes against Iran

The Age 7/02/2012 | ISRAEL'S Foreign Minister was headed for Washington overnight amid signs that the US and its Middle East ally hold diverging views on how best to resolve the standoff over Iran's disputed nuclear program.

Ryan misses out on Perpetual love

Sydney Morning Herald 7/02/2012 | There will be fewer love hearts and boxes of chocolates this Valentine's Day for the short-lived chief executive of Perpetual Limited, Chris Ryan.

Hotel upgrades aimed at rising domestic demand

Sydney Morning Herald 7/02/2012 | HOTEL owners and operators are preparing for a busy year of openings and renovations as demand increases from domestic travellers.

Catch some rays and head into blue heaven

The Age 6/02/2012 | AUSTRALIA has a reputation for embracing technological developments quickly. We had a record take-up of VHS, DVD and widescreen television, and it is widely claimed that the Land of Oz has more home theatres per head of population than anywhere else in the world.

In the final analysis, Pete had the good oil

Sun Herald 5/02/2012 | INVESTORS cheered during the week, perhaps convinced that the latest rearrangement of deckchairs on the good ship euro will do the trick and right the heavily listing vessel.

If you can't beat banks, join 'em

Sun Herald 5/02/2012 | David Potts reveals why having a stake in a lender is so much more profitable than being its customer  dividends.

More...


Sponsored Links

More from our network...